Oral vs Injectable BPC-157: What Each Route Has Actually Been Tested For
No published human study has given BPC-157 by mouth or by subcutaneous injection. What the record shows for each route, and what it cannot tell you.
The short version
BPC-157 is sold as capsules and as injections, and people argue about which works better. The published human record cannot settle that. The FDA found no published study that gave BPC-157 to people by mouth or by subcutaneous injection, and no human absorption data for either route. The rodent studies it reviewed used oral dosing and injection into the abdomen, which is not how BPC-157 is sold.
- No published human study has tested oral BPC-157 or subcutaneous BPC-157.
- No human absorption or half-life data exist for either route, so neither can be ranked.
- The rodent studies the FDA reviewed used oral dosing or injection into the abdomen, in gut and liver models.
- The FDA says injected and nasal peptides generally carry more immune-reaction risk than oral ones.
The oral vs injectable BPC-157 argument runs on forums as though one side has data. Neither does. The human record has no published study of BPC-157 taken by mouth and none of it injected under the skin. Those are two of the forms it is sold in. Nasal spray is a third, and it has no published human study either.
This page sets out what has been measured for each route, in what species and by what method. It does not recommend a route or a dose, because the record cannot support either.
US legal status - Research use only
Sold for laboratory research use only. Not approved by the FDA for human use, and cannot be lawfully marketed as a supplement or a medicine. Products sold this way are not made to pharmaceutical quality standards, and their contents are not verified by anyone.
AU legal status - Not on the ARTG
Not on the Australian Register of Therapeutic Goods, so the TGA has not assessed it for safety, quality or effectiveness. Goods that are not on the ARTG cannot lawfully be supplied or advertised in Australia except through a specific pathway - the Special Access Scheme, an Authorised Prescriber, a clinical trial, or personal importation.
Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.
Side by side
| Oral (capsules, oral spray) | Injectable (subcutaneous vials) | |
|---|---|---|
| How it is sold | FDA lists oral capsule and oral spray among marketed forms | FDA lists injectable product among marketed forms |
| Published human studies by this route | None located by FDA | None located by FDA |
| Registered but unpublished | One phase 1 oral-tablet study in healthy volunteers in Mexico; no results posted, no publication found | None described by FDA |
| Human pharmacokinetics | None | None |
| Animal efficacy work (as summarised by FDA) | Rat studies with the peptide in drinking water or by gavage, in gut and liver injury models | The injected rat studies FDA summarised used injection into the abdominal cavity, not under the skin |
| Animal toxicity studies by this route | None identified by FDA | None identified by FDA |
| FDA view on immune reactions | Inherent immunogenic risk “likely to be low” | Subcutaneous route generally associated with more immunogenicity |
| Sport (WADA 2026) | Prohibited at all times (S0) | Prohibited at all times (S0) |
The table is drawn from the FDA’s briefing document for the July 2026 Pharmacy Compounding Advisory Committee meeting. FDA reviewers searched PubMed and Embase for every human study of BPC-157, so the rows marked “none” are FDA’s search results, not mine alone.
Full evidence page: BPC-157
What the human record contains, by route
The FDA’s inventory comes to five published studies in roughly 80 people. Sorted by route, the gap is clear.
The only randomised placebo-controlled trial in patients used an enema, in ulcerative colitis. It did not show a significant benefit and exists only as a meeting abstract. The other enema study, in healthy volunteers, was placebo-controlled but tested tolerability, not benefit. Every other human study was uncontrolled.
“Injectable” in that record means a clinician injecting a specific site: a joint, the bladder, a vein. None was the under-the-skin self-injection that research-chemical vials are sold for. Evidence from an injection into a knee does not transfer to an injection into the abdomen.
Oral BPC-157: what is known
In people: nothing published. The FDA did find one registered phase 1 study, in healthy volunteers in Mexico, comparing an oral tablet with placebo. No results are posted and the FDA could not find a publication. A registered study with no results is a plan, not a finding.
In rodents: some. In the rat studies the FDA summarised, BPC-157 was given in drinking water or by gavage, alongside injection into the abdominal cavity. The models were colonic fistula, NSAID-induced stomach and gut lesions, and liver injury. The authors reported effects by both routes. The FDA added its own caveats: no dose-response relationship was established, some studies lacked tissue analysis, and the molecular targets remain unidentified.
The FDA evaluated BPC-157 for ulcerative colitis, so it summarised gut and liver models. It did not tally routes across the wider musculoskeletal literature, and neither have I. The tendon and muscle studies behind the recovery marketing are not covered by this route comparison.
This next point is my inference, not a finding. Those models are injuries to the gut and liver, the organs an oral dose reaches first. A peptide could act on a gut lesion without ever entering the bloodstream. That makes these studies weak evidence for oral BPC-157 acting on a tendon or a joint.
On stomach survival: the claim that BPC-157 resists breakdown in gastric juice comes from laboratory work, and the FDA briefing repeats it from an in vitro report. I have not verified it independently. Even if it holds, surviving the stomach is not absorption. No study has measured how much of an oral dose reaches the blood, in people or, according to the FDA, in animals.
Studied in cells or animals. No controlled trials in humans. Oral route only. The rat studies the FDA summarised gave BPC-157 in drinking water or by gavage, in gut and liver injury models. No published human study of oral BPC-157 exists; one registered phase 1 study has no posted results. No oral bioavailability data in any species, per the FDA.
Injectable BPC-157: what is known
In people: no published study of subcutaneous injection. Three human studies used other injection routes, each given by a clinician. None was randomised.
- Into the knee joint: a retrospective review of 17 patients with no control group.
- Into the bladder: 12 people with interstitial cystitis.
- Intravenously: two healthy people.
In rodents: the injected studies the FDA summarised used intraperitoneal injection, into the abdominal cavity. Nobody sells BPC-157 for that. The animal pharmacokinetic and toxicity work the FDA described used intravenous and intramuscular dosing. The FDA found no study establishing bioavailability by the subcutaneous route and no animal toxicity study by that route.
On immune reactions: the FDA states that subcutaneous and nasal routes are generally associated with more immunogenicity than oral or rectal routes. It adds that BPC-157, a 15-amino-acid peptide given by injection or nasally, “may pose a significant risk for immunogenicity”, possibly worsened by aggregation and impurities. No study has formally investigated the immunogenicity of any BPC-157 product.
Studied in cells or animals. No controlled trials in humans. Subcutaneous route only. No published human study of subcutaneous BPC-157. The human injection studies used the knee joint, the bladder or a vein, and none was controlled. The injected rat studies the FDA summarised used the abdominal cavity, and the FDA found no bioavailability or toxicity data for subcutaneous dosing.
What neither route has
Some gaps are shared, and they matter more than the differences between routes.
- No human pharmacokinetics. The FDA found no human pharmacokinetic data for BPC-157 by the oral or subcutaneous route. In the two enema studies, BPC-157 was not detected in plasma. The FDA concluded there is no information to assess its pharmacokinetics in humans.
- No confirmed human efficacy. A review states that most studies were done in small rodent models and that efficacy is yet to be confirmed in humans Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159., in the references below. A more recent review says regulators have not approved it because comprehensive clinical studies confirming benefit in humans are absent Józwiak 2025 - Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2)., in the references below.
- No verified product. The FDA flags peptide-related impurities as a concern even for the oral route, where it rates the inherent immune risk as low. Capsules and vials from the research-chemical market carry the same uncertainty about what is in them.
The mechanism work does not help either side. The mechanistic study cited across my BPC-157 pages measured VEGFR2 signalling in cultured cells, chick membrane assays and rats Hsieh 2017 - Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333., in the references below. Cells in a dish receive the peptide directly, so that work says nothing about which route delivers it to a tissue in a person.
Where the FDA process stands
The FDA evaluated BPC-157 for one use, ulcerative colitis, and its staff proposed not adding it to the 503A Bulks List. The routes it assessed were oral, subcutaneous, nasal, rectal and transdermal. That was a staff proposal made before the committee met. The Pharmacy Compounding Advisory Committee met on 23-24 July 2026 and voted 8-6, with one abstention, to recommend letting pharmacies compound BPC-157 (ABC News). The vote is advice, not a rule. FDA has not yet published a final decision.
Related
- BPC-157: what the research shows
- BPC-157 benefits
- BPC-157 vs TB-500
- BPC-157 dosage: the common protocol
- Oral peptides: which work as capsules or pills
- Research peptides and the law
Common questions
Is oral BPC-157 better than injectable BPC-157?
The published human record cannot answer that. In its briefing document for the July 2026 advisory committee meeting, the FDA found no published study that gave BPC-157 to people by mouth or by subcutaneous injection. It also found no human pharmacokinetic data for either route. Any ranking of the two rests on no human measurement.
Is oral BPC-157 absorbed?
Nobody has measured it in people. The claim that BPC-157 survives stomach acid comes from laboratory work, and surviving the stomach is not the same as crossing into the blood. In the two human studies that gave it as an enema, BPC-157 was not detected in plasma. The FDA wrote that it does not appear to be absorbed systemically by that route.
Has subcutaneous BPC-157 been tested in humans?
Not in any published study the FDA could find. In the human record, a clinician injected it into the knee joint or the bladder, or gave it intravenously to two people. None of those is the under-the-skin injection that research-chemical vials are sold for.
Which route does the FDA consider riskier?
The FDA states that subcutaneous and nasal routes are generally associated with more immunogenicity than oral or rectal routes. It says the inherent immune risk of oral BPC-157 is likely to be low. Its concerns about impurities apply regardless of route. This is a statement about immune reactions, not an endorsement of either route.
What dose of BPC-157 is used orally or by injection?
The common protocol is for injection: 250 to 500 mcg under the skin, once or twice daily, for 4 to 8 weeks, then a 2 to 4 week break. That is common practice, not trial-established. The detail is on /bpc-157-dosage/. I found no human pharmacokinetic study for oral or subcutaneous use, so a dose for either route rests on numbers nobody has measured in people.
Is the pill form of BPC-157 good?
There is no evidence either way. No published human study has tested an oral BPC-157 capsule for effectiveness, and FDA found no oral bioavailability data in any species. Product quality is also unverified. FDA reviewed the certificates of analysis it could find. Most show only a purity result, with no impurity-limit testing to show the impurity profile is controlled.
Is BPC-157 hard on your liver?
No human data exist, and the animal data raise more questions than they answer. A 28-day intramuscular dosing study reported no organ damage on gross exam in rats or dogs. The exception was a liver-specific finding in dogs that FDA's summary does not describe further. FDA noted that the histopathology data were not included in the published article, so none of this can be independently checked. The same study found liver-related blood-test changes: raised ALT, glucose and triglycerides in rats, and raised triglycerides and potassium in dogs. Separate rodent studies used BPC-157 to protect against liver injury from other causes. FDA found no dose-response relationship in those protective studies. Neither set of studies used the oral or subcutaneous routes this page compares.
Does BPC-157 mess with your heart?
There is no human evidence on this. Some sellers market BPC-157 for "cardiac health," a claim FDA quoted in its review without endorsing it. The same 28-day intramuscular dosing study in rats and dogs recorded no meaningful difference in ECG readings between treated and control dogs. Its authors reported no heart-related finding on gross exam. FDA noted that the histopathology data were not included in the published article, so that finding cannot be independently checked. The study did not use the oral or subcutaneous routes this page compares, and no cardiac safety study of either route exists.
Are there any negative side effects of BPC-157?
Few have been reported, but the record is thin, not clean. FDA's search of its adverse-event database found 3 reports through December 2025, all involving an injectable product. They were injection-site redness and swelling, breathlessness severe enough for an emergency-room visit, and skin and gum darkening that recurred when the person used the product again. Across the five small published human studies, FDA found no serious adverse events. The most common complaints after enema dosing were headache and flatulence. No case reports exist in the published literature, and none of this covers oral use.
Which peptide does Joe Rogan take?
The one peptide Joe Rogan has named in a statement confirmed by two sources is BPC-157. In July 2021 he said on his podcast that it cleared elbow tendonitis within two weeks. He also said he had an NAD drip, which is not a peptide, while ill with COVID-19. Neither statement says what he takes now; see /joe-rogan-peptides/. Peptides that come up in this kind of discussion, including BPC-157, are research chemicals with no FDA approval for any use. The FDA found no published human study of BPC-157 taken by mouth or by subcutaneous injection, the two forms most commonly sold. See my BPC-157 evidence page and my research peptides and the law page for what is established.
References (8 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.ReviewPMID 30915550
- 2.Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2).ReviewPMID 40005999full text
- 3.Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333.StudyPMID 27847966
- 4.The Joe Rogan Experience #1683 (with Andrew Huberman), 14 July 2021, episode transcript: Rogan describes elbow tendonitis cleared after starting BPC-157.- Podscripts (episode transcript)other
- 5.FDA briefing document for the Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026 - evaluation of BPC-157-related bulk drug substances, including routes proposed, human studies by route, human pharmacokinetics and immunogenicity by route.- US Food and Drug Administrationregulatory
- 6.FDA - July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (meeting page and event materials).- US Food and Drug Administrationregulatory
- 7.WADA 2026 Prohibited List - BPC-157 named under S0, non-approved substances, prohibited at all times (national anti-doping agency mirror, PDF).- World Anti-Doping Agency, mirrored by the Jamaica Anti-Doping Commissionregulatory
- 8.ABC News, 23 July 2026 - FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list (8-6, one abstention).- ABC Newsnews